Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Yi‐Long Wu's publication output changed over time?
ScholarIQpublication output · 2009–2020
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2020.
1
2
1
2
1
3
1
1
20092011201320142015201620192020
What are the most-cited papers on Yi‐Long Wu?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
New England Journal of Medicine. 20098,284 CitationsOPEN ACCESS
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw, Kari Chansky, John Crowley, Ramón Rami–Porta, Hisao Asamura, Wilfried Eberhardt, Andrew G. Nicholson, Patti A. Groome, Alan Mitchell, Vanessa Bolejack, Peter Goldstraw, Ramón Rami–Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy J. Giroux, Fergus Gleeson, Patti A. Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Antoon Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan P. van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna K. Nowak, Michael Peake, Thomas W. Rice, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Nagahiro Saijo, Paul Van Schil, Jean‐Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William D. Travis, Ming‐Sound Tsao, Andrew T. Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp H. Kernstine, Hedy L. Kindler, Lee M. Krug, Kristiaan Nackaerts, Harvey I. Pass, David C. Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene H. Blackstone, F. Abad Cavaco, Emilio Ansótegui Barrera, J. Abal Arca, Isaura Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, David Ball, G.K. Bascom, Ana Isabel Blanco Orozco, M.A. González Castro, Matthew G. Blum, Domingo Chimondeguy, Vlado Cvijanović, Sebastián Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, Felipe Andreo García, Kwun M. Fong, Gloria Francisco Corral
Journal of Thoracic Oncology. 20164,703 CitationsOPEN ACCESS
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
The Lancet Oncology. 20114,112 Citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
New England Journal of Medicine. 20133,411 CitationsOPEN ACCESS
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares
The Lancet. 20163,375 CitationsOPEN ACCESS
Related on ScholarIQ
Xihua University
Institution
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Paper
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Paper
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Paper
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Paper
Lung cancer: current therapies and new targeted treatments
Paper